Tiger Brokers

Solid Biosciences Q4 net loss widens on higher R&D costs

Reuters
Mar 20
<a href="https://laohu8.com/S/SLDB">Solid Biosciences</a> Q4 net loss widens on higher R&D costs

Overview

  • US genetic medicine developer's Q4 net loss widened yr/yr, driven by higher R&D expenses

Outlook

  • Solid anticipates cash runway to extend into H1 2028 after $240 mln private placement

Result Drivers

  • SGT-003 COSTS - Higher R&D expenses were mainly due to increased manufacturing and clinical costs for SGT-003

  • PERSONNEL EXPENSES - R&D and G&A expenses rose due to higher personnel-related costs

  • PIPELINE ADVANCEMENT - Increased expenses also reflected progress in other pipeline programs, including SGT-601 and SGT-501

Company press release: ID:nGNX6lWz98

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

-$49.8 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 124.7% above its March 18 closing price of $7.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10